ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Core Points - ORIC Pharmaceuticals, Inc. granted inducement equity awards to three new non-executive employees on June 3, 2024, consisting of 30,000 non-qualified stock options and 4,800 restricted stock units [1][2] - The inducement grants are part of the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan and are contingent on the recipients' continued employment [2][3] - The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date, with a vesting schedule that includes 25% vesting after one year and the remainder vesting monthly thereafter [2] - One-third of the restricted stock units will vest on each of the first three anniversaries of the Grant Date [2] Company Overview - ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing treatments that address mechanisms of therapeutic resistance in cancer [4] - The company's product candidates include ORIC-114, ORIC-944, and ORIC-533, targeting various cancer types and resistance mechanisms [4] - ORIC is also developing multiple precision medicines aimed at overcoming cancer resistance [4]